GE HealthCare Technologies enters its July 28 earnings date with an unusually clean insider buying signal — one that predates, and arguably anticipated, the stock's modest recovery from its April lows.
The insider story here is the standout. Following the April 29 earnings selloff, which knocked the stock down more than 11% in a single session, nearly every senior name on the cap table stepped in to buy. The CEO purchased shares worth roughly $250,000, the CFO added $200,000, and independent director H. Lawrence Culp — the former GE chief — committed $5 million at around $61.88. Several other board members followed. Net insider buying over the 90 days through late May reached $6.77 million across more than 109,000 shares. That's a coordinated signal, not a one-off; and the stock has clawed back to $64.89 since, up about 1.4% on the week.
Positioning in the lending market does nothing to complicate the picture. Short interest at 3.6% of the free float is modest, though it has risen roughly 42% over the past month — from around 11.5 million shares in early June to 16.4 million now — suggesting a gradual rebuild rather than a panic. Borrow remains very cheap at 0.46%, barely changed from a month ago. Availability is extremely loose at 2,694%, meaning there are roughly 27 shares available for every one currently borrowed. This is well above the 52-week trough of 1,124%, and short sellers face no meaningful squeeze pressure. Options positioning is mildly more defensive than its recent norm, with the put/call ratio at 0.62 against a 20-day average of 0.59 — a z-score of just over one — but the deviation is minor and nowhere near alarm territory. Overall, positioning looks cautious but not crowded.
The Street's view on GEHC is anchored firmly in neutral territory, though with a notable recent outlier. After the April earnings miss, Goldman Sachs downgraded to Neutral and cut its target from $81 to $65, while JPMorgan, Citi, and Barclays all trimmed targets to similar levels while holding their ratings. The mean price target currently sits at $79.44, implying roughly 22% upside from current prices — but much of that gap reflects pre-downgrade targets that haven't been refreshed. The most recent action came from RBC Capital, which initiated coverage in late June with an Outperform rating and an $80 target, adding a fresh constructive voice. The factor score picture adds texture: GEHC ranks in the 95th percentile on analyst recommendation divergence — an unusually wide spread between bulls and bears — and in the 94th percentile on dividend score, while short score and sector score both sit at the midpoint. The PE multiple of 12x and EV/EBITDA around 8.5x have compressed modestly over the past month, with PB down about 6% over seven days, reflecting the stock's flat-to-slightly-lower drift since early June.
The bull case rests on China market recovery, new product introductions in precision care, and recurring revenue resilience. Bears point to competition from United Imaging and Siemens Healthineers, tariff exposure, and the prospect that the April guidance cut has not yet fully reset expectations. Among the stock's closest correlated peers, BAX gained 3.8% on the week and ICUI added 5%, while CNMD dipped 0.5% — a mixed backdrop that offers no clear sector-level tailwind or headwind for GEHC heading into its print.
The earnings record adds an important caveat to the insider-buying narrative. The May report produced a benign 2.8% one-day move, but the April print delivered an 11.2% drop followed by a 9.9% drawdown over five days — one of the sharper reactions in the peer group. With Q2 results due July 28, the question shaping up for the next three weeks is whether the guidance reset after April was sufficient, or whether macro and tariff pressures have continued to weigh on order flow in the intervening quarter.
See the live data behind this article on ORTEX.
Open GEHC on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
